As of 2024-12-03, the EV/EBITDA ratio of Karyopharm Therapeutics Inc (KPTI) is -2.76. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. KPTI's latest enterprise value is 297.16 mil USD. KPTI's TTM EBITDA according to its financial statements is -107.56 mil USD. Dividing these 2 quantities gives us the above KPTI EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.6x - 16.7x | 15.4x |
| Forward P/E multiples | 14.8x - 17.9x | 15.8x |
| Fair Price | (14.23) - (15.84) | (14.92) |
| Upside | -1783.8% - -1974.7% | -1865.0% |
| Date | EV/EBITDA |
| 2024-11-29 | -2.76 |
| 2024-11-27 | -2.77 |
| 2024-11-26 | -2.80 |
| 2024-11-25 | -2.76 |
| 2024-11-22 | -2.76 |
| 2024-11-21 | -2.68 |
| 2024-11-20 | -2.68 |
| 2024-11-19 | -2.68 |
| 2024-11-18 | -2.70 |
| 2024-11-15 | -2.73 |
| 2024-11-14 | -2.75 |
| 2024-11-13 | -2.79 |
| 2024-11-12 | -2.82 |
| 2024-11-11 | -2.85 |
| 2024-11-08 | -2.80 |
| 2024-11-07 | -2.81 |
| 2024-11-06 | -2.81 |
| 2024-11-05 | -2.76 |
| 2024-11-04 | -2.87 |
| 2024-11-01 | -2.83 |
| 2024-10-31 | -2.93 |
| 2024-10-30 | -2.76 |
| 2024-10-29 | -2.77 |
| 2024-10-28 | -2.83 |
| 2024-10-25 | -2.74 |
| 2024-10-24 | -2.73 |
| 2024-10-23 | -2.77 |
| 2024-10-22 | -2.77 |
| 2024-10-21 | -2.77 |
| 2024-10-18 | -2.79 |
| 2024-10-17 | -2.77 |
| 2024-10-16 | -2.77 |
| 2024-10-15 | -2.75 |
| 2024-10-14 | -2.77 |
| 2024-10-11 | -2.78 |
| 2024-10-10 | -2.77 |
| 2024-10-09 | -2.77 |
| 2024-10-08 | -2.76 |
| 2024-10-07 | -2.79 |
| 2024-10-04 | -2.81 |
| 2024-10-03 | -2.80 |
| 2024-10-02 | -2.81 |
| 2024-10-01 | -2.66 |
| 2024-09-30 | -2.75 |
| 2024-09-27 | -2.62 |
| 2024-09-26 | -2.60 |
| 2024-09-25 | -2.59 |
| 2024-09-24 | -2.60 |
| 2024-09-23 | -2.59 |
| 2024-09-20 | -2.64 |